NCT03116321View on ClinicalTrials.gov

Bioequivalence of Two Different Sources of Eslicarbazepine Acetate

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 3, 2016

Primary Completion Date

January 5, 2017

Study Completion Date

January 5, 2017

Conditions
Epilepsy
Interventions
DRUG

Eslicarbazepine acetate (ESL)

Oral Tablet of 800 mg and 200 mg of ESL

All Listed Sponsors
lead

Bial - Portela C S.A.

INDUSTRY

NCT03116321 - Bioequivalence of Two Different Sources of Eslicarbazepine Acetate | Biotech Hunter | Biotech Hunter